Innovative Patent Publication by Clearmind Medicine
Clearmind Medicine Inc. (NASDAQ: CMND) has made an exciting announcement regarding its latest patent publication aimed at addressing cocaine addiction.
Research Backed by Leading Experts
The patent, recently published by the Korean Intellectual Property Office, reveals Clearmind's cutting-edge combination therapy utilizing MEAI and N-Acylethanolamines. This innovative approach leverages findings from preclinical trials conducted by Professor Gal Yadid and his team at Bar-Ilan University in Israel.
Significant Findings from Preclinical Trials
In these pivotal trials, animals treated with MEAI showcased a notable decrease in cravings associated with cocaine use. Further studies indicated that MEAI effectively reduces cocaine-seeking behavior without compromising the animals' responsiveness to natural rewards. This crucial result underscores MEAI's targeted action on addiction mechanisms rather than general reward pathways.
Collaborative Efforts with SciSparc Ltd.
Clearmind's patent publication is a part of its strategic collaboration with SciSparc Ltd. (NASDAQ: SPRC), focusing on integrating Clearmind's groundbreaking MEAI therapy with SciSparc's PEA. This partnership highlights the commitment of both companies to develop effective treatments for central nervous system disorders.
About Clearmind Medicine Inc.
Clearmind is dedicated to discovering and developing new psychedelic-based therapeutics that address significant health challenges, including addiction. Their mission extends to commercializing these compounds as regulated medicines, foods, or supplements.
Intellectual Property Portfolio
The company boasts an impressive array of nineteen patent families, which includes 31 granted patents. Clearmind remains proactive in seeking additional patents to fortify its intellectual property, ensuring a robust platform for their unique therapeutic innovations.
Stock and Financial Information
Shares of Clearmind Medicine are actively traded on the Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange as "CWY0." Investors keen on the psychedelic therapy sector may take a close look at this stock as Clearmind progresses on its innovative path.
Company Contact Information
For inquiries, you can reach out to Clearmind's investor relations through email at invest@clearmindmedicine.com or by telephone at (604) 260-1566. Additional information can be found on their official website: www.clearmindmedicine.com.
Frequently Asked Questions
What is Clearmind Medicine known for?
Clearmind Medicine is focused on developing psychedelic-derived treatments that address major health issues like addiction.
What therapy has Clearmind patented?
They have patented a combination therapy utilizing MEAI and N-Acylethanolamines for cocaine addiction treatment.
Who conducted the preclinical trials for Clearmind's research?
The trials were conducted by Professor Gal Yadid and his research team at Bar-Ilan University in Israel.
How does MEAI therapy work?
MEAI therapy is designed to reduce cravings for cocaine without affecting the desire for natural rewards.
Where can I find more information about Clearmind Medicine?
You can visit their website at www.clearmindmedicine.com for more details.
